Photo: Fred Hutch
Education, Training, Board Certifications
- M.D., University of Chicago
- Residency, Hospital of the University of Pennsylvania
- Fellowship in Medical Oncology, UW/Fred Hutch
- Medical Oncology, American Board of Internal Medicine
Clinical Expertise
- Immunotherapy
- CAR T-cell therapy
- Hematopoietic stem cell transplantation
- Lymphoma
Affiliations
Publications
Research and/or clinical interests
Dr. Brian Till develops new treatments for lymphoma by genetically engineering a patient's own T cells so they can more effectively attack cancer. T cells target and kill cancer cells by binding to specific proteins on the tumor cells with molecules called T-cell receptors. Dr. Till's research involves making synthetic receptors known as chimeric antigen receptors, or CARs, that home in on lymphoma cells. He led the first published trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till continues to carry out a variety of immunological, genetic and gene-expression studies in the clinic to understand why CAR T-cell therapies work for some patients and fail for others. This research will help improve the next iterations of this experimental therapy.
